Motley Fool19d agoneutral
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
Insider Monkey88d agobullish
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBCGilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
Insider Monkey118d agobullish
Gilead (GILD) Wins FDA Approval for First HDV Treatment HepcludexGilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Stocks to Invest In. On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the […]
Stocktwits125d agobullish
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV TreatmentU.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.